‘Glowing skin’ lands Amazon, Tata 1mg on FSSAI radar; marine collagen powder under scanner
Source Entity
The Indian Express
The FSSAI has issued show-cause notices to Tata 1mg, ACFO Pharmaceuticals, Amazon, and Flipkart regarding regulatory violations in the marketing of marine collagen powder. The scrutiny focuses on improper labeling and misleading claims about the product's medicinal properties.
Regulatory Scrutiny Over Marine Collagen Marketing
The Food Safety and Standards Authority of India (FSSAI) has initiated a significant regulatory action by issuing show-cause notices to major stakeholders in the health supplement market, including Tata 1mg Healthcare Solutions, manufacturer ACFO Pharmaceuticals, and e-commerce giants Amazon and Flipkart. This intervention centers on the marketing and labeling of "TATA 1mg Marine collagen powder," a product that has been heavily promoted for its purported "glowing skin" benefits. By targeting both the manufacturers and the platforms facilitating these sales, the FSSAI is signaling a stricter enforcement of safety and transparency standards in the rapidly expanding nutraceutical sector.
The Core Allegations: Labeling and Compliance
At the heart of the FSSAI’s investigation are specific violations regarding mandatory product disclosures. The regulatory framework in India, governed by the Food Safety and Standards Act, requires that health supplements carry specific warnings, such as the statement "not for medicinal use," printed in a clear, bold format. The regulator has alleged that these requirements were not met on the packaging of the marine collagen powder. Failure to include such warnings poses a risk of misleading consumers into believing that these supplements can treat or cure dermatological conditions, thereby blurring the line between dietary supplements and pharmaceutical drugs.
The Role of E-commerce Platforms
By serving notices to Amazon Seller Services Pvt Ltd and Flipkart India Pvt Ltd, the FSSAI is holding online marketplaces accountable for the products listed on their platforms. As e-commerce continues to dominate the retail landscape for health and wellness products, this move underscores the regulator's expectation that platforms exercise due diligence. E-commerce entities are no longer seen as mere intermediaries but as key participants in the supply chain who must ensure that the products they host comply with national safety standards and advertising guidelines.
Implications for the Nutraceutical Industry
This case highlights the broader challenges facing the Indian nutraceutical industry, where marketing claims often outpace regulatory compliance. The "glowing skin" narrative used to promote collagen products represents a massive market segment driven by social media trends and beauty influencers. However, the FSSAI’s intervention serves as a reminder that health claims must be substantiated and that mandatory labeling is non-negotiable. This enforcement action is likely to force companies to audit their entire product portfolios to ensure that marketing materials do not inadvertently promise medicinal outcomes that have not been clinically validated for over-the-counter supplements.
Future Trends and Consumer Protection
Looking ahead, we can expect the FSSAI to intensify its monitoring of digital storefronts and health supplement advertisements. As consumers become more health-conscious, the demand for transparency in ingredients and labeling will only increase. This development likely signals the beginning of a more rigorous regulatory environment where e-commerce platforms must implement stricter internal verification processes for health-related listings. For consumers, this is a positive step toward ensuring that the products they purchase for aesthetic and health benefits are accurately represented and clearly labeled according to established safety protocols.